Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the efficacy and safety of Recombinant Human
Tissue-Type Plasminogen Activator Derivative(rPA) and Recombinant Tissue-Type Plasminogen
Activator(rt-PA) for the treatment of acute pulmonary embolism.
This trial includes two stages, the first stage is to study the dosage of administration of
the test drug(rPA), the second is to compare the efficacy and safety of rPA and rt-PA. Both
of the two stages are randomized, open and parallel controlled.